Pharmacokinetic evaluation of decitabine for the treatment of leukemia

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 5, 2011, Pages 661-672

  Bryan, Jeffrey ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute myeloid leukemia; decitabine; leukemia; metabolism; pharmacokinetics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE; IDARUBICIN; IMATINIB; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GERIATRIC PATIENT; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NONHUMAN; PNEUMONIA; SOLID TUMOR; SOMNOLENCE; STEADY STATE; VOMITING;

AGE FACTORS; AGED; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES;

EID: 79955076625     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.575062     Document Type: Article

References (102)

1. Brenet F, Moh M, Funk P, et al. Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment [abstract]. Blood 2009;114:591
2. Egger G, Gangning L, Aparicio A, et al. Epigenetics in human disease and prospects for epignentic therapy. Nature 2004;429:457-63 (Pubitemid 38715140)
3. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation-a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96 (Pubitemid 27435555)
4. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 1999;59:3730-40 (Pubitemid 29381880)
5. Baylin SB, Hoppener JW, de Bustros A, et al. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 1986;46:2917-22 (Pubitemid 16074305)
6. Jones PA, Wolkowicz MJ, Rideout WM III, et al. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc Natl Acad Sci USA 1990;87:6117-21
7. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7 (Pubitemid 29070360)
8. Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitts lymphoma is associated with 5′ CpG island methylation. Cancer Res 1999;59:3352-6 (Pubitemid 29334490)
9. Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 1999;94:1113-20 (Pubitemid 29361845)
10. Issa JPJ, Baylin SB, Herman JG. DNA Methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 1997;11(Suppl 1):S7-11 (Pubitemid 27197352)
11. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997;90(4):1403-9 (Pubitemid 27355412)
12. Herman JG, Civin CI, Issa JP, et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997;57:837-41 (Pubitemid 27098005)
13. Jones PA, Taylor SM. Cellular differentiation, cytidine analogues and DNA methylation. Cell 1980;20:85-93 (Pubitemid 10117303)
14. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5 azacytosine. Proc Natl Acad Sci U S A 1984;81:6993-7 (Pubitemid 15216684)
15. van Groeningen C, Leyva A, OBrien A, et al. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 1986;46:4831-6 (Pubitemid 16000370)
16. Rivard G, Momparler R, Demers J, et al. Phase I study on 5-aza-2 deoxycytidine in children with acute leukemia. Leuk Res 1981;5:453-62 (Pubitemid 12252112)
17. Pliml J, Sorm F. Synthesis of 2-deoxy-D-ribofuranosyl- 5-azacytosine. Collect Czech Chem Commun 1964;29:2576-7
18. Pinto A, Zagonel V. 5-Aza-2′- deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993;7(Suppl 1):51-60 (Pubitemid 23184801)
19. Momparler RL, Bouchard J, Onetto N, et al. 5-aza-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leuk Res 1984;8:181-5 (Pubitemid 14149195)
20. Petti M, Mandelli F, Zagonel V, et al. Pilot study of 5-aza-2′- deoxycytidine (decitabine) in the treatment of poor prognosis acute myeloid leukemia patients: preliminary results. Leukemia 1993;7(Suppl 1):36-41 (Pubitemid 23184798)
21. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100:2957-64
22. Bender CM, Pao MM, Jones PA. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998;58:95-101 (Pubitemid 28027723)
23. Pinto A, Zagonel V, Attadia V, et al. 5-aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 1989;4(Suppl 2):28-32 (Pubitemid 20110666)
24. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 1983;43:3493-6 (Pubitemid 13026595)
25. Pinto A, Attadia V, Fusco A, et al. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984;64(4):922-9
26. Limonta M, Colombo T, Damia G, et al. Cytotoxic activity and mechanism of action of 5-aza-2′-deoxycytidine in human CML cells. Leuk Res 1993;17:977-82 (Pubitemid 23330150)
27. Blum W, Bruner-Klisovic R, Liu S, et al. Phase I study of low dose decitabine in patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Blood 2005;106:1861
28. Issa JPJ, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40 (Pubitemid 38268953)
29. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myeloid leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-56 (Pubitemid 46218698)
30. Sacchi S, Kantarjian HM, OBrien S, et al. Chronic myeloid leukemia in nonlymphoid blastic phase. Cancer 1999;86:2632-41
31. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794-803
32. WijerMans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for Intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and german MDS study groups [abstract]. Blood 2008;112:226
33. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009;27:3842-8
34. Rogstad DK, Herring JL, Theruvathu JA, et al. Chemical decomposition of 5-aza-2′-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 2009;22:1194-204
35. Chan KK, Giannini DD, Staroscik JA, Sadee W. 5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy. J Pharm Sci 1979;68:807-12 (Pubitemid 9224244)
36. Hajek M, Votruba I, Holy A, et al. Alpha anomer of 5-aza-2′- deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells. Biochem Pharmacol 2008;75:965-72 (Pubitemid 351181426)
37. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13 (Pubitemid 351705186)
38. Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2′- deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007;67:6400-8 (Pubitemid 47037524)
39. Lin KT, Momparler RL, Rivard GE. High performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 1981;70:1228-32 (Pubitemid 12166545)
40. Liu Z, Marcucci G, Byrd JC, et al. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006;20:1117-26
41. Jutterman R, Li E, Jaenisch R. Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-801
42. Rogstad DK, Herring JL, Theruvathu JA, et al. Chemical decomposition of 5-aza-2′-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 2009;22:1194-204
43. Momparler R, BouVard D, Momparler L, et al. Pilot phase I-II study on 5-aza-2-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997;8(4):358-68 (Pubitemid 27204954)
44. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2-deoxycytidine. Cancer Chemother Pharmacol 2003;51:231-9 (Pubitemid 36469953)
45. Momparler R, Rivard G, Gyger M. Clinical trial on 5-aza-2′- deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985;30:277-86 (Pubitemid 17207209)
46. Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2′-deoxycytidine in rabbits and dogs. Cancer Res 1983;43:592-7 (Pubitemid 13193853)
47. Dacogen [package insert]. SuperGen Inc.Dublin CA 2010
48. Amanda F. Cashen AF, Shah AK, et al. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008;61:759-66 (Pubitemid 351302031)
49. Zagonel, V, Lo Re G, Marotta G, et al. 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 1993;7(Suppl 1):30-5 (Pubitemid 23184797)
50. Wijermans PW, Krulder JW, Huijgens PC, et al. Continuous infusion of low-dose 5-Aza-2′- deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997;11:1-5 (Pubitemid 27065040)
51. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-62 (Pubitemid 30123770)
52. Wijerman PW, Lubbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS;the experience with DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84(Suppl 1):9-17
53. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96(12):3671-4
54. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7 (Pubitemid 46053042)
55. Cheson BD, Greenber PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25 (Pubitemid 44061337)
56. Goldberg SL, Steensma DP. Myelodysplastic syndrome patients obtaining a cytogenetic response to outpatient decitabine experience improved hematological responses and longer survival: additional analyses from the ADOPT trial [abstract]. Blood 2009;114:3817
57. Kantarjian HM, OBrien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133-7 (Pubitemid 46435392)
58. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
59. Oki Y, Kantarjian HM, OBrien S, et al. Phase II Study of decitabine in combination with imatinib mesylate in patients with accelerated (AP) or blastic phase (BP) of chronic myeloid leukemia (CML) [abstract]. Blood 2005;106:1099
60. Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2′- deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 1993;7(Suppl 1):49-50 (Pubitemid 23184800)
61. Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the efects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 1997;11(Suppl 1):24-7
62. Issa JPJ, Saba HI, Garcia-Manero G, et al. Decitabine in older patients with acute myeloid leukemia (AML) [abstract]. J Clin Oncol 2007;25:7021
63. Danilov AV, Smith H, Relias V, et al. Outpatient decitabine in elderly patients with acute myeloid leukemia (AML) [abstract]. Blood 2009;114:4144
64. Cashen AF, Schiller GJ, ODonnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28(4):556-61
65. Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007;2007(1):405-11
66. Kondo Y, Shen L, Yan PS, et al. Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci USA 2004;101:7398-403 (Pubitemid 38638044)
67. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6 (Pubitemid 46184355)
68. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-9 (Pubitemid 39166498)
69. Yang H, Hoshino K, Sanchez-Gonzalez B, et al. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk Res 2005;29(7):739-48 (Pubitemid 40779480)
70. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108(10):3271-9
71. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-91 (Pubitemid 47477265)
72. Issa JP, Castoro R, Ravandi-Kashani F, et al. Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML [abstract]. Blood 2008;112:228
73. Ravandi F, Faderl S, Thomas D, et al. Phase I study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia [abstract]. Blood 2007;110:897
74. Kirschbaum M, Gojo I, Goldberg SL, et al. Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): a phase I, dose-escalation study [abstract]. Blood 2009;114:2089
75. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21(35):5483-95 (Pubitemid 34983483)
76. Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 2007;8(1):65-73 (Pubitemid 46070830)
77. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010;116(16):3830-4
78. Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008;49:690-5 (Pubitemid 351517213)
79. National Cancer Institute. Surveillance epidemiology and end results stat facts sheets. cancer: acute meyloid leukemia. Available from: http://seer.cancer.gov/statfacts/html/clyl.html [Accessed 1 Sep 2010]
80. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30
81. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-6
82. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59
83. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48
84. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903 (Pubitemid 24299870)
85. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of post remission therapy in acute myeloid leukemia. Blood 1992;79:1924-30
86. Elonen E, Almqvist A, Hanninen A, et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia 1998;12:1041-8 (Pubitemid 28349798)
87. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-5
88. Menzin J, Boulanger L, Karsten V, et al. Effects of initial treatment on survival among elderly AML patients: findings from the SEER-Medicare Database [abstract]. Blood 2006;108:1973
89. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25(14):1908-15 (Pubitemid 46854425)
90. Rowe JM, Neuberg D, Friedenberg W, et al. Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103(2):479-85 (Pubitemid 38140076)
91. Kantarjian H, OBrien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-8
92. Lang K, Earle C, Foster T, et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 2006;22(11):943-55
93. de Lima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myeloid leukemia in patients aged 80 years and above. Br J Haematol 1996;93(4):89-93
94. Goldstone AH, Burnett A, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98(5):1302-11
95. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24 (Pubitemid 46435390)
96. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia. J Clin Oncol 1988;6:583-7
97. Robles C, Kim KM, Oken MM, et al. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia 2000;14:1349-53 (Pubitemid 30599314)
98. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of the European Organisation for the Research and Treatment of Cancer and the Dutch Belgium Hemato-Oncology Cooperative Group. Blood 1997;90:2952-61
99. Rees JKH, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost: principal report of the Medical Research Councils AML9 study. Br J Haematol 1996;94:89-98 (Pubitemid 26232545)
100. Lubbert M, Bertz H, Ruter B, et al. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009;44:585-8
101. Yang H, Thomas DA, Rytting ME, et al. Phase I study of frequent low-dose administration of decitabine, alone or in combination with hyperCVAD, in relapsed or refractory acute lymphocytic leukemia (ALL) [abstract]. J Clin Oncol 2007;25:7072
102. Blum W, Garzon R, Klisovik RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with 10-day schedule of decitabine. PNAS 2010;107:7473-8